1. Home
  2. SSM vs IMNN Comparison

SSM vs IMNN Comparison

Compare SSM & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SSM

Sono Group N.V. Ordinary Shares

N/A

Current Price

$6.90

Market Cap

10.6M

Sector

N/A

ML Signal

N/A

Logo Imunon Inc.

IMNN

Imunon Inc.

HOLD

Current Price

$2.95

Market Cap

11.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSM
IMNN
Founded
N/A
1982
Country
Germany
United States
Employees
43
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6M
11.0M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
SSM
IMNN
Price
$6.90
$2.95
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$182.61
AVG Volume (30 Days)
1.6K
17.3K
Earning Date
N/A
03-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.34
$0.37
52 Week High
$10.47
$9.32

Technical Indicators

Market Signals
Indicator
SSM
IMNN
Relative Strength Index (RSI) 44.67 35.79
Support Level $6.70 $0.43
Resistance Level $7.00 $3.16
Average True Range (ATR) 0.13 0.23
MACD -0.04 -0.02
Stochastic Oscillator 9.09 11.64

Price Performance

Historical Comparison
SSM
IMNN

About SSM Sono Group N.V. Ordinary Shares

Sono Group NV is engaged in the field of solar-powered electric mobility. With its proprietary solar technology, the company is able to integrate solar panels into a vehicle's bodywork, using energy captured from the sun to charge the vehicle's battery. The group is engaged in the design and development of its own first solar electric vehicle, the Sion. Its Products and Services includes Complete Solar Solutions, Solar Charge Controllers, Solar Modules, and Data Services and Engineering Services.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Share on Social Networks: